{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:35Z","timestamp":1786980575935,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Fundamental Research Funds for the Central Universities","award":["YD9110002017"],"award-info":[{"award-number":["YD9110002017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Primary Sj\u00f6gren\u2019s Syndrome (pSS) falls within the category of connective tissue diseases, characterized by the presence of autoantibodies such as antinuclear antibodies (ANA). However, according to the classification criteria for pSS, some patients may exhibit a negative result for autoantibodies. Patients with a negative result for autoantibodies may lack typical features of connective tissue diseases, and the immunological state as well as the extent of organ involvement and damage may differ from those with positive autoantibodies. This study aims to compare the clinical phenotypes of patients with positive and negative autoantibodies, providing insights for disease classification and treatment selection for clinicians. Patients with pSS were grouped based on the presence and titers of their autoantibodies. Subsequently, differences in organ damage and laboratory indicators were compared between these groups, aiming to analyze the value of autoantibody titers in assessing the condition of pSS. (1) Patients with positive ANA exhibited elevated levels of inflammatory indicators, including ESR, IgG levels, lip gland biopsy pathology grade, and overall organ involvement, in comparison with patients with negative ANA (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). Furthermore, ANA-positivity correlated with a higher occurrence of multi-organ damage, particularly affecting the skin, mucous membranes, and the hematological system (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). (2) As ANA titers increased, patients demonstrated elevated levels of IgG and an escalation in organ involvement (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). (3) Patients in the positive autoantibody group (positive for antinuclear antibodies, anti-SSA, or anti-SSB antibodies) had higher IgG levels compared to the negative group (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). (4) Patients with positive anti-SSA and anti-SSB antibodies exhibited higher levels of inflammatory indicators and IgG compared to other patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05); however, no significant differences were observed in terms of organ involvement and organ damage. Patients with positive ANA in pSS typically exhibit higher levels of inflammation and an increased likelihood of experiencing multi-organ damage. Furthermore, as the ANA titers increase, both inflammation levels and the risk of multi-organ damage also escalate. Additionally, the presence of anti-SSA and anti-SSB antibodies may contribute to an elevated risk of increased inflammation levels, but does not increase the risk of organ damage.\n                  <\/jats:p>","DOI":"10.1007\/s10238-024-01357-5","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T04:01:51Z","timestamp":1715140911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The titers of antinuclear antibodies are associated with the degree of inflammation and organ damage in Primary Sj\u00f6gren's Syndrome"],"prefix":"10.1007","volume":"24","author":[{"given":"Huijun","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"issue":"3","key":"1357_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7150\/ijms.17718","volume":"14","author":"T Both","year":"2017","unstructured":"Both T, Dalm VA, Van Hagen PM, Van Daele PL. Reviewing primary Sj\u00f6gren\u2019s syndrome: beyond the dryness\u2014from pathophysiology to diagnosis and treatment. Int J Med Sci. 2017;14(3):191\u2013200.","journal-title":"Int J Med Sci"},{"issue":"3","key":"1357_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/jpm10030105","volume":"10","author":"M Boothe","year":"2020","unstructured":"Boothe M, Morris R, Robin N. Stickler syndrome: a review of clinical manifestations and the genetics evaluation. J Pers Med. 2020;10(3):105.","journal-title":"J Pers Med"},{"issue":"1","key":"1357_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","volume":"22","author":"S Negrini","year":"2022","unstructured":"Negrini S, Emmi G, Greco M, Borro M, Sardanelli F, Murdaca G, Indiveri F, Pup-po F. Sj\u00f6gren\u2019s syndrome: a systemic autoimmune disease. Clin Exp Med. 2022;22(1):9\u201325.","journal-title":"Clin Exp Med"},{"issue":"3","key":"1357_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","volume":"42","author":"A Fayyaz","year":"2016","unstructured":"Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sj\u00f6gren\u2019s Syndrome. Rheum Dis Clin North Am. 2016;42(3):419\u201334.","journal-title":"Rheum Dis Clin North Am"},{"issue":"7","key":"1357_CR5","first-page":"980","volume":"20","author":"F Andr\u00e9","year":"2022","unstructured":"Andr\u00e9 F, B\u00f6ckle BC. Sj\u00f6gren\u2019s syndrome. J Dtsch Dermatol Ges. 2022;20(7):980\u20131002.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"Suppl","key":"1357_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/eos.12536","volume":"126","author":"R Jonsson","year":"2018","unstructured":"Jonsson R, Brokstad KA, Jonsson MV, Delaleu N, Skarstein K. Current concepts on Sj\u00f6gren\u2019s syndrome\u2014classification criteria and biomarkers. Eur J Oral Sci. 2018;126(Suppl):37\u201348.","journal-title":"Eur J Oral Sci"},{"issue":"11","key":"1357_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.autrev.2015.07.002","volume":"14","author":"L Quartuccio","year":"2015","unstructured":"Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L, Alunno A, Colafrancesco S, Luciano N, Giacomelli R, Gerli R, Valesini G, Bombardieri S, De Vita S. Anti-SSA\/SSB-negative Sj\u00f6gren\u2019s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015;14(11):1019\u201322.","journal-title":"Autoimmun Rev"},{"key":"1357_CR8","unstructured":"Tarn JR, Howard-Tripp N, Lendrem DW, Mariette X, Saraux A, Devauchelle-Pensec V, Seror R, Skelton AJ, James K, McMeekin P, Al-Ali S, Hackett KL, Lendrem BC, Hargreaves B, Casement J, Mitchell S, Bowman SJ, Price E, Pease CT, Emery P, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Johnsen SJA, Norheim KB, Omdal R, Stocken D, Everett C, Fernandez C; Leeds CTRU; Isaacs JD, Gottenberg JE; French ASSESS cohort; Ng WF; UK Primary Sj\u00f6gren's Syndrome Registry. Symptom-based stratification of patients with primary Sj\u00f6gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 2019;1(2): e85\u2013e94."},{"key":"1357_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h6819","volume":"352","author":"SC Mathai","year":"2016","unstructured":"Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352: h6819.","journal-title":"BMJ"},{"issue":"2","key":"1357_CR10","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2021.020502","volume":"31","author":"A Te\u0161ija Kuna","year":"2021","unstructured":"Te\u0161ija Kuna A, \u0110erek L, Drvar V, Kozmar A, Gugo K. Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine. Biochem Med (Zagreb). 2021;31(2): 020502.","journal-title":"Biochem Med (Zagreb)"},{"key":"1357_CR11","doi-asserted-by":"crossref","unstructured":"Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown RM, Morgan P, Bombardieri S, Ng WF, Tzioufas AG, Vitali C, Shirlaw P, Haacke E, Costa S, Bootsma H, Devauchelle-Pensec V, Radstake TR, Mariette X, Richards A, Stack R, Bowman SJ, Barone F; Sj\u00f6gren's histopathology workshop group (appendix) from ESSENTIAL (EULAR Sj\u00f6gren's syndrome study group). Standardisation of labial salivary gland histopathology in clinical trials in primary Sj\u00f6gren's syndrome. Ann Rheum Dis. 2017;76(7):1161\u20131168.","DOI":"10.1136\/annrheumdis-2016-210448"},{"issue":"04","key":"1357_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/CM9.0000000000000626","volume":"59","author":"W Zhang","year":"2020","unstructured":"Zhang W, Li X, Xu D, et al. Diagnosis and treatment of primary Sjogren\u2019s syndrome. Chin Med J. 2020;59(04):269\u201376.","journal-title":"Chin Med J"},{"issue":"9","key":"1357_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","volume":"9","author":"G Nocturne","year":"2013","unstructured":"Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sj\u00f6gren\u2019s syndrome. Nat Rev Rheumatol. 2013;9(9):544\u201356.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"1357_CR14","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1002\/art.11311","volume":"48","author":"S Salomonsson","year":"2003","unstructured":"Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmstr\u00f6m P, Wahren-Herlenius M, Jonsson R. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sj\u00f6gren\u2019s syndrome. Arthritis Rheum. 2003;48(11):3187\u2013201.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1357_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.autrev.2010.05.006","volume":"9","author":"MM Varin","year":"2010","unstructured":"Varin MM, Le Pottier L, Youinou P, Saulep D, Mackay F, Pers JO. B-cell tolerance breakdown in Sj\u00f6gren\u2019s syndrome: focus on BAFF. Autoimmun Rev. 2010;9(9):604\u20138.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1357_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/ard.62.2.168","volume":"62","author":"X Mariette","year":"2003","unstructured":"Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis. 2003;62(2):168\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1357_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.autrev.2018.09.003","volume":"18","author":"E Mart\u00edn-Nares","year":"2019","unstructured":"Mart\u00edn-Nares E, Hern\u00e1ndez-Molina G. Novel autoantibodies in Sj\u00f6gren\u2019s syndrome: A comprehensive review. Autoimmun Rev. 2019;18(2):192\u20138.","journal-title":"Autoimmun Rev"},{"key":"1357_CR18","doi-asserted-by":"crossref","unstructured":"Shiboski CH, Shiboski SC, Seror R, et al. International Sj\u00f6gren's Syndrome Criteria Working Group. 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9\u201316.","DOI":"10.1136\/annrheumdis-2016-210571"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01357-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01357-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01357-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T12:18:15Z","timestamp":1732969095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01357-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1357"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01357-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no Conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Our protocols for the collection and processing of animal and human samples were approved by the Medical Research Ethics Committee (2023-RE-279) of the First Hospital of the University of Science and Technology of China (Anhui Provincial Hospital), respectively.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"96"}}